Mohammed Milhem

13PUBLICATIONS
138CO-AUTHORS
Molecular targetsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem

|Jul 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes

|Jun 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.

Diwakar Davar, Zeynep Eroglu, Mohammed Milhem

|Feb 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

|Jun 28, 2023
Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.

Espen B Ellingsen, Steven O'Day, Artur Mezheyeuski

|Mar 31, 2023
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.

Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski

Pageof 3

Frequent Collaborators

2 joint publications

Scott H Okuno

2 joint publications

Umang Swami

2 joint publications

Gregory A Daniels

2 joint publications

Georgina V Long